EVUSHELD STORAGE, DOSING & ADMINISTRATION GUIDE

EVUSHELD is a combination of 2 long-acting monoclonal antibodies (LAABs), tixagevimab and cilgavimab.

AUTHORIZED USE

EVUSHELD™ (tixagevimab co-packaged with cilgavimab) is authorized for use under an Emergency Use Authorization (EUA) for the pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 **and**
  - Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments **and** may not mount an adequate immune response to COVID-19 vaccination **or**
  - For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

EVUSHELD may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., anti-infectives).

EVUSHELD has been authorized by FDA for the emergency use described above. EVUSHELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.

EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

LIMITATIONS OF AUTHORIZED USE

- EVUSHELD is not authorized for use in individuals:
  - For treatment of COVID-19, or
  - For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.
- Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
- In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.

IMPORTANT SAFETY INFORMATION

EVUSHELD™ (tixagevimab co-packaged with cilgavimab) has not been approved, but has been granted an Emergency Use Authorization (EUA) by FDA. There are limited clinical data available and serious and unexpected adverse events may occur that have not been previously reported with EVUSHELD use.

Please see additional Important Safety Information throughout and see Fact Sheet for Healthcare Providers for information on the authorized use of EVUSHELD and mandatory requirements of the EUA.

AstraZeneca

EVUSHELD™
(tixagevimab co-packaged with cilgavimab)

EVUSHELD STORAGE, DOSING & ADMINISTRATION GUIDE

EVUSHELD is a combination of 2 long-acting monoclonal antibodies (LAABs), tixagevimab and cilgavimab.

STORAGE

EACH EVUSHELD CARTON CONTAINS TWO VIALS; ONE OF EACH ANTIBODY. EACH VIAL CONTAINS AN OVERFILL TO ALLOW THE WITHDRAWAL OF 150 MG (1.5 ML)

VIAL 1: tixagevimab solution for injection (dark grey vial cap)

VIAL 2: cilgavimab solution for injection (white vial cap)

- **The solutions are sterile, preservative-free, clear to opalescent and colorless to slightly yellow solutions.**

STORE UNOPENED VIALS IN A REFRIGERATOR AT 2°C TO 8°C (36°F TO 46°F) IN THE ORIGINAL CARTON TO PROTECT FROM LIGHT. DISCARD ANY UNUSED PORTION

- **Do not freeze. Do not shake**

IM=intramuscular.

DOSING

EVUSHELD IS ADMINISTERED BY INTRAMUSCULAR INJECTION

EVUSHELD dose*

Antibody dose	Number of vials needed	Volume to withdraw from vial(s)
tixagevimab 150 mg	1 vial (dark grey cap)	1.5 mL
cilgavimab 150 mg	1 vial (white cap)	1.5 mL

*150 mg of tixagevimab and 150 mg of cilgavimab are to be administered as separate, consecutive intramuscular injections.

ADMINISTRATION

STEP-BY-STEP PROCESS

1. Remove carton of EVUSHELD from **refrigerated storage**

2. **Visually inspect** the vials for particulate matter and discoloration. Discard the vials if the solution is **cloudy, discolored, or visible particles are observed**

3. Withdraw 1.5 mL of tixagevimab solution and 1.5 mL of cilgavimab solution into **TWO separate syringes. Discard unused portion in vials.**

4. Administer the IM injections at **different injection sites**, preferably one in each of the gluteal muscles, one after the other

5. Clinically monitor individuals after injections and observe for at least 1 hour

IMPORTANT SAFETY INFORMATION (Cont'd)

Contraindication:

EVUSHELD is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to any component of EVUSHELD.

Warnings and Precautions:

Hypersensitivity Including Anaphylaxis
Serious hypersensitivity reactions, including anaphylaxis, have been observed with IgG1 monoclonal antibodies like EVUSHELD. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive therapy. Clinically monitor individuals after injections and observe for at least 1 hour.

Clinically Significant Bleeding Disorders
As with any other intramuscular injection, EVUSHELD should be given with caution to individuals with thrombocytopenia or any coagulation disorder.

Please see additional Important Safety Information throughout and see Fact Sheet for Healthcare Providers for information on the authorized use of EVUSHELD and mandatory requirements of the EUA.

Please see EVUSHELD.com for more detailed information.

AstraZeneca

EVUSHELD™
(tixagevimab co-packaged with cilgavimab)

IMPORTANT SAFETY INFORMATION (Cont'd)

Warnings and Precautions (Cont'd)

Cardiovascular Events

A higher proportion of subjects who received EVUSHELD versus placebo reported myocardial infarction and cardiac failure serious adverse events. All of the subjects with events had cardiac risk factors and/or a prior history of cardiovascular disease at baseline. A causal relationship between EVUSHELD and these events has not been established. Consider the risks and benefits prior to initiating EVUSHELD in individuals at high risk for cardiovascular events, and advise individuals to seek immediate medical attention if they experience any signs or symptoms suggestive of a cardiovascular event.

Adverse Reactions:

The most common adverse events are headache, fatigue and cough.

Use in Specific Populations:

Pregnancy

There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. EVUSHELD should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

Lactation

There are no available data on the presence of tixagevimab or cilgavimab in human milk or animal milk, the effects on the breastfed infant, or the effects of the drug on milk production. Maternal IgG is known to be present in human milk.

Pediatric Use

EVUSHELD is not authorized for use in pediatric individuals under 12 years of age or weighing less than 40 kg. The safety and effectiveness of EVUSHELD have not been established in pediatric individuals.

AUTHORIZED USE

EVUSHELD™ (tixagevimab co-packaged with cilgavimab) is authorized for use under an EUA for the pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 **and**
  - Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments **and** may not mount an adequate immune response to COVID-19 vaccination **or**
  - For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

EVUSHELD may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., anti-infectives).

EVUSHELD has been authorized by FDA for the emergency use described above. EVUSHELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.

EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

LIMITATIONS OF AUTHORIZED USE

- EVUSHELD is not authorized for use in individuals:
  - For treatment of COVID-19, or
  - For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2
- Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination
- In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination

See Full Fact Sheet for Healthcare Providers for examples of medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination, the justification for emergency use of drugs during the COVID-19 pandemic, information on available alternatives, and additional information on COVID-19.

The FDA Letter of Authorization is available for reference, as well as the Fact Sheet for Patients, Parents And Caregivers.

SARS-CoV-2 Viral Variant

There is a potential risk of treatment failure due to the development of viral variants that are resistant to tixagevimab and cilgavimab administered together. Prescribing healthcare providers should consider the prevalence of SARS-CoV-2 variants in their area, where data are available, when considering prophylactic treatment options.

Reporting Adverse Events

The prescribing healthcare provider and/or your designee must report all SERIOUS ADVERSE EVENTS and MEDICATION ERRORS potentially related to EVUSHELD within 7 calendar days from the healthcare provider's awareness of the event (1) by submitting FDA Form 3500 online, (2) by downloading FDA Form 3500 and then submitting by mail or fax, or (3) contacting the FDA at 1-800-FDA-1088 to request this form.

In addition, please fax a copy of all FDA MedWatch forms to AstraZeneca at 1-866-742-7984.

Report adverse events by visiting https://contactazmedical.astrazeneca.com, or calling AstraZeneca at 1-800-236-9933.

Please see additional Important Safety Information throughout and see Fact Sheet for Healthcare Providers for information on the authorized use of EVUSHELD and mandatory requirements of the EUA.

AstraZeneca

EVUSHELD™

(tixagevimab co-packaged with cilgavimab)